40
Participants
Start Date
December 3, 2018
Primary Completion Date
July 21, 2020
Study Completion Date
December 20, 2021
Daratumumab
"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
Kingston Health Sciences Centre, Kingston
Princess Margaret Cancer Centre, Toronto
Hôpital Maisonneuve-Rosemont, Montreal
McGill University Health Centre, Montreal
Hôpital de l'Enfant-Jésus, Québec
Saskatoon Cancer Centre, Saskatoon
Lead Sponsor
Canadian Myeloma Research Group
OTHER